436 related articles for article (PubMed ID: 32654458)
1. [Clinical characteristics and prognostic analysis of advanced-stage extranodal NK/T cell lymphoma].
Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):462-468. PubMed ID: 32654458
[No Abstract] [Full Text] [Related]
2. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Characteristics and Prognostic Analysis of Extranodal NK/T-Cell Lymphoma Patients Treated with Pegaspargase Based Chemotherapy].
Wei C; Zhang Y; Wang W; Zhang L; Zhang W; Zhou DB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):735-740. PubMed ID: 34105466
[TBL] [Abstract][Full Text] [Related]
4. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
[TBL] [Abstract][Full Text] [Related]
5. [Extranodal NK/T-cell lymphoma, nasal type: a clinical analysis].
Chen F; Shen CX; Wang HG; Li GX; Wang XQ; Wen Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Mar; 31(5):327-333. PubMed ID: 29871255
[No Abstract] [Full Text] [Related]
6. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
7. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
[TBL] [Abstract][Full Text] [Related]
8. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
[TBL] [Abstract][Full Text] [Related]
9. [Analysis on Clinical Characteristics and Prognosis of 47 Patients with Extranodal NK/T Cell Lymphoma].
Li QH; Yang P; Wang JJ; Dong F; Tian L; Wan W; Ke XY; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):86-90. PubMed ID: 33554802
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.
Wang ZY; Liu QF; Wang H; Jin J; Wang WH; Wang SL; Song YW; Liu YP; Fang H; Ren H; Wu RY; Chen B; Zhang XM; Lu NN; Zhou LQ; Li YX
Blood; 2012 Sep; 120(10):2003-10. PubMed ID: 22826562
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus.
Zhao Q; Fan S; Chang Y; Liu X; Li W; Ma Q; Li Y; Wang Y; Zhang L; Zhang M
Cancer Manag Res; 2019; 11():3555-3564. PubMed ID: 31118779
[No Abstract] [Full Text] [Related]
12. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of autologous hematopoietic stem cell transplantation in the treatment of advanced/recurrent nasal type extranodal NK/T-cell lymphoma].
Yuan FF; Yin QS; Fu YW; Wang Q; Chen L; Mi RH; Li YF; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):569-572. PubMed ID: 30122016
[No Abstract] [Full Text] [Related]
15. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
[TBL] [Abstract][Full Text] [Related]
16. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
Wei W; Wu P; Li L; Zhang ZH
Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
[TBL] [Abstract][Full Text] [Related]
19. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
[TBL] [Abstract][Full Text] [Related]
20. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
